303 related articles for article (PubMed ID: 32802167)
1. Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma.
Zeng Z; Yang B; Liao ZY
Oncol Lett; 2020 Oct; 20(4):45. PubMed ID: 32802167
[TBL] [Abstract][Full Text] [Related]
2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
3. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment.
Leone P; Solimando AG; Fasano R; Argentiero A; Malerba E; Buonavoglia A; Lupo LG; De Re V; Silvestris N; Racanelli V
Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34065489
[TBL] [Abstract][Full Text] [Related]
4. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
[TBL] [Abstract][Full Text] [Related]
5. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy.
Zhang J; Hu C; Xie X; Qi L; Li C; Li S
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992198
[TBL] [Abstract][Full Text] [Related]
7. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma.
Pourhamzeh M; Asadian S; Mirzaei H; Minaei A; Shahriari E; Shpichka A; Es HA; Timashev P; Hassan M; Vosough M
Mol Cell Biochem; 2023 Jan; 478(1):23-37. PubMed ID: 35708866
[TBL] [Abstract][Full Text] [Related]
8. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
9. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
10. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A
Front Oncol; 2018; 8():269. PubMed ID: 30057891
[TBL] [Abstract][Full Text] [Related]
11. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC.
Marzi L; Mega A; Gitto S; Pelizzaro F; Seeber A; Spizzo G
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884392
[TBL] [Abstract][Full Text] [Related]
12. Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model.
Sové RJ; Verma BK; Wang H; Ho WJ; Yarchoan M; Popel AS
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323435
[TBL] [Abstract][Full Text] [Related]
13. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.
Abdelrahim M; Esmail A; Saharia A; Abudayyeh A; Abdel-Wahab N; Diab A; Murakami N; Kaseb AO; Chang JC; Gaber AO; Ghobrial RM
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406533
[TBL] [Abstract][Full Text] [Related]
14. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
Ouyang T; Kan X; Zheng C
Front Oncol; 2022; 12():898964. PubMed ID: 35785169
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.
Onuma AE; Zhang H; Huang H; Williams TM; Noonan A; Tsung A
Gene Expr; 2020 Jun; 20(1):53-65. PubMed ID: 32340652
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
Tao S; Liang S; Zeng T; Yin D
Front Immunol; 2022; 13():1043667. PubMed ID: 36685594
[TBL] [Abstract][Full Text] [Related]
19. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
Feng MY; Chan LL; Chan SL
Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review.
Sharafi F; Hasani SA; Alesaeidi S; Kahrizi MS; Adili A; Ghoreishizadeh S; Shomali N; Tamjidifar R; Aslaminabad R; Akbari M
Cancer Cell Int; 2022 Aug; 22(1):269. PubMed ID: 35999569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
